A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK
Hilary Glen, Amit Bahl, Louisa Fleure, Noel Clarke, Suneil Jain, Tania Kalsi, Vincent Khoo, Junaid Mobeen · 2024
Read A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK by Hilary Glen, Amit Bahl, Louisa Fleure, Noel Clarke, Suneil Jain, Tania Kalsi, Vincent Khoo, Junaid Mobeen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11603693.txt.
Description
Hilary Glen and seven co-authors convene UK specialists to settle when a three-drug prostate cancer regimen is worth its weight. Their 2024 consensus study addresses hormone-sensitive cancer that has already spread. The triplet stacks hormone therapy, chemotherapy, and a receptor-targeted drug. An eight-member steering group drafted thirty-nine statements on its use, then put them to a wider anonymous vote.
One hundred twenty clinicians answered, mostly oncologists. Thirty-seven of the thirty-nine statements won consensus, and over two thirds won it overwhelmingly. From the agreed statements the steering group built practical recommendations for spotting the patients who should get all three drugs. The authors present the exercise as a map for clinics: the triplet is powerful, its costs are real, and matching it to the right patients is how its promise becomes better outcomes.
Catalog record
| CREATOR | Hilary Glen, Amit Bahl, Louisa Fleure, Noel Clarke, Suneil Jain, Tania Kalsi, Vincent Khoo, Junaid Mobeen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |